Structure‐Based Development of Ultra‐Broad‐Spectrum 3C‐Like Protease Inhibitors
Advanced Science · 2026-02 · 13 (11)
DOI: 10.1002/advs.202512342 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 12.12.2025. Verfasst von Haixia Su und 15 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China. Hauptthemen laut MEDLINE: Antiviral Agents, Coronavirus 3C Proteases, Protease Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Plan of China, Hubei Natural Science Foundation for Distinguished Young Scholars.
Abstract (Originalsprache)
Recurrence of coronavirus outbreaks and zoonotic origins of human coronaviruses underscore the importance of developing pan‐coronavirus antivirals. The highly conserved 3C‐like protease (3CL pro ) in coronaviruses, together with the well‐established druggability, makes it an ideal target for broad‐spectrum antiviral therapeutics. Here, the inhibitory activity of approved 3CL pro inhibitors, including nirmatrelvir, ensitrelvir, and simnotrelvir, against fifteen 3CL pro s is first reported by enzymatic assays. Despite their potent inhibition toward 3CL pro s of β‐CoVs, these inhibitors show reduced potency against 3CL pro s from the other three genera, particularly against two newly identified human coronaviruses (α‐CCoV‐HuPn‐2018 and δ‐PDCoV). In this context, continued efforts in structure‐based optimization of nirmatrelvir lead to the identification of compound 8 that potently inhibits a panel of 32 3CL pro s across all subgenera (IC 50 s: 19–146 n m ), with an IC 50 value of 61 and 81 n m against α‐CCoV‐HuPn‐2018 and δ‐PDCoV 3CL pro s, respectively. Moreover, it effectively inhibits nirmatrelvir‐resistant 3CL pro mutants and demonstrates broad‐spectrum antiviral efficacy in cells. These findings suggest an important rule that a small, non‐cyclic P2 segment and a P4 segment with a suitable size are preferred by the design of ultra‐broad‐spectrum 3CL pro inhibitors, and provide a proof‐of‐concept guide for developing broad‐spectrum antivirals as potential pan‐CoV therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
- University of Chinese Academy of Sciences, Beijing, 100049, China.
- Lingang Laboratory, Shanghai, 200031, China.
- School of Physical Science and Technology, ShanghaiTech University, Shanghai, 201210, China.
- School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, 310024, China.
- State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, 430071, China.
ORCID-Profile: Yechun Xu
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Plan of China
- Hubei Natural Science Foundation for Distinguished Young Scholars
- Chinese Academy of Sciences
Zitieren
APA
Su, H., Nie, T., Chen, G., Xiong, M., Zhang, Y., Wu, G., You, M., Xie, H., He, J., Xiong, Y., Hu, H., Zhao, W., Li, M., Xiao, G., Zhang, L., & Xu, Y. (2026). Structure‐Based Development of Ultra‐Broad‐Spectrum 3C‐Like Protease Inhibitors. Advanced Science, 13(11). https://doi.org/10.1002/advs.202512342
Vancouver
Su H, Nie T, Chen G, Xiong M, Zhang Y, Wu G, et al. Structure‐Based Development of Ultra‐Broad‐Spectrum 3C‐Like Protease Inhibitors. Advanced Science. 2026;13(11). doi:10.1002/advs.202512342
BibTeX
@article{Su2026,
author = {Su, Haixia and Nie, Tianqing and Chen, Guofeng and Xiong, Muya and Zhang, Yumin and Wu, Guoqing and You, Mengyuan and Xie, Hang and He, Jian and Xiong, Yanchao and Hu, Hangchen and Zhao, Wenfeng and Li, Minjun and Xiao, Gengfu and Zhang, Leike and Xu, Yechun},
title = {Structure‐Based Development of Ultra‐Broad‐Spectrum 3C‐Like Protease Inhibitors},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {11},
doi = {10.1002/advs.202512342}
}
EUVIMED